Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01032902 · ClinicalTrials.gov registry record
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
A clinical trial of HIV Infections, sponsored by Chembio Diagnostic Systems.
- Completed
- Registry status
- 2,808
- Enrollment target
- 5
- Study locations
NCT01032902: Completed study of HIV Infections, sponsored by Chembio Diagnostic Systems.
NCT01032902 is a study of HIV Infections that has completed, run by Chembio Diagnostic Systems. The registered enrollment target is 2,808 participants, above the 441-participant average among 542 other HIV Infections trials with a reported enrollment target (537% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01032902, a study of HIV Infections, has completed, sponsored by Chembio Diagnostic Systems.
- COMPLETED
- Registry status
- 2,808 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 rapid test. The device is intended to qualitatively detect the presence of antibodies against HIV-1/2 in oral fluid, whole blood (capillary and venous), serum or plasma. This study will assess the DPP® HIV 1/2 Screen assay's ability to detect HIV-1.
Conditions Studied
Interventions
- DEVICE In Vitro Diagnostic Device
Study Locations (5)
California
- Univeristy of California, San Diego - La Jolla
Florida
- Therafirst - Fort Lauderdale
Maryland
- University of Maryland - Baltimore
Pennsylvania
- St. Christopher's Hospital for Children/ Drexel University College of Medicine - Philadelphia
Texas
- University of Texas HSC - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,808 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-04 |
What the finished NCT01032902 record still lists
NCT01032902 is an observational study that tracks outcomes without assigning an intervention. Its 2,808 participants enrollment target places it among the larger protocols in the corpus, above the 441-participant average among 542 other HIV Infections trials with a reported enrollment target (537% higher).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which In Vitro Diagnostic Device is the first listed.
NCT01032902 lists 5 locations in 5 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT01032902 about?
NCT01032902 is a clinical study titled "Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test". This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 rapid test. The device is intended to qualitatively detect the presence of antibodies against HIV-1/2 in oral fluid, whole blood (capillary and venous), serum or plasma. This study will ass...
What is the current status of trial NCT01032902?
This trial is currently completed. The enrollment target is 2,808 participants. The study started on 2010-01. Estimated completion is 2012-04.
What conditions does trial NCT01032902 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT01032902?
The interventions under investigation include: In Vitro Diagnostic Device (DEVICE).
Who is sponsoring clinical trial NCT01032902?
This trial is sponsored by Chembio Diagnostic Systems, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01032902 being conducted?
This trial has 5 study locations across California, Florida, Maryland, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01032902's enrollment target sits among peer trials
2,808 8th of 542 higher than 535 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05932602 · 2,812 participants
AVEIR DR Coverage With Evidence Development (CED) Study
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia